Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication CANASA is indicated in adults for the treatment of mildly to moderately active ulcerative proctitis. CANASA is an aminosalicylate indicated in adults for the treatment of mildly to moderately active ulcerative proctitis. ( 1 ) FDA label
Also known as SPD476, Lialda, mesalazine, MMX mesalamine, Asacol
Mesalamine · 7 trials · 4 indications
Clinical response was defined as partial ulcerative colitis disease activity index (UC-DAI) score \< or =1 with rectal bleeding = 0, stool frequency \< or =1, and physician's global assessment (PGA = 0). Number of participants with clinical response were reported.
Clinical response was defined as partial UC-DAI \<=1 with (rectal bleeding = 0, stool frequency \< or =1, and PGA = 0). Number of participants who had maintained clinical response were reported.
Recurrence of diverticulitis is defined as the presence of each and all of the following 3 items: 1) abdominal pain, 2) a 15% increase in white blood cell count from baseline, 3) bowel wall thickening (\>5 mm) and/or fat stranding as evidenced by spiral computerized axial tomography (CT) scan; OR surgical intervention for diverticular disease. Withdrawals are considered as recurrences.
Endoscopic remission is defined as an endoscopy score of less than or equal to 1. Endoscopy score (mucosal appearance) ranges from 0-3 (0 = normal \[intact vascular pattern; no friability or granulation\], 1 = mild \[erythema; decreased vascular pattern; minimal granularity\], 2 = moderate \[marked erythema; granularity; friability; absent vascular pattern; bleeding with minimal trauma; no ulcerations\], 3 = severe \[ulceration; spontaneous bleeding\].
A taste assessment was completed immediately after investigational product was administered to assess the subject's taste/liking of the formulation. The assessment consisted of a 5-point rating scale. Participants were asked to choose one of the following responses to the statement "The taste was acceptable": strongly agree, agree, neutral, disagree, or strongly disagree. The number of participants who chose either of the top two responses (strongly agree, agree) is reported.
An aftertaste assessment was completed 5 minutes after administration of investigational product to assess whether the participants detected an aftertaste. The participants answered "Yes" or "No" to the following question: "Was there an aftertaste?" The number of participants who answered "Yes" is reported.
An aftertaste assessment was completed 5 minutes after administration of investigational product to assess the subject's rating of aftertaste and means of administration. The assessment consisted of a 5-point rating scale. The participants were asked to choose one of the following responses to the statement "The aftertaste (if present) was acceptable": strongly agree, agree, neutral, disagree, or strongly disagree. The number of participants who chose either of the top two responses (strongly agree, agree) is reported.
The participants were asked to answer "Yes" or "No" to the following question: "Would you be willing to take medicine this way on a regular basis if necessary?" The number of participants who answered "Yes" is reported.
AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.
Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.
Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.
Clearance of a substance from the blood by the kidneys.
| Arm | Type | Description |
|---|---|---|
| MMX Mesalamine/Mesalazine (Low Dose) | EXPERIMENTAL | Once daily, tablets - the amount depends on the participants weight; 900 milligram per day (mg/day) for participants weighing 18 kg to less than or equal to (\<=) 23 kilograms (kg); 1200 mg/day for participants weighing greater than (\>) 23 kg to \<= 35 kg; 1800 mg/day for participants weighing \> 35 kg to \<= 50 kg; 2400 mg/day for participants weighing \> 50 kg to \<= 90 kg. |
| MMX Mesalamine/Mesalazine (High Dose) | EXPERIMENTAL | Once daily, tablets - the amount depends on the participants weight;1800 mg/day for participants weighing 18 kg to \<= 23 kg; 2400 mg/day for participants weighing \> 23 kg to \<= 35 kg; 3600 mg/day for participants weighing \> 35 kg to \<= 50 kg; 4800 mg/day for participants weighing \> 50 kg to \<= 90 kg. |
| SPD476 (1.2 g) | EXPERIMENTAL | - |
| SPD476 (2.4 g) | EXPERIMENTAL | - |
| SPD476 (4.8 g) | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| SPD476 | EXPERIMENTAL | Mesalazine |
| Asacol | ACTIVE_COMPARATOR | - |
| Mesalamine (Vanilla Yogurt) | EXPERIMENTAL | One 500mg capsule contents sprinkled onto 1 tablespoon of low-fat vanilla yogurt |
| Mesalamine (Applesauce) | EXPERIMENTAL | One 500mg capsule contents sprinkled onto 1 tablespoon of applesauce |
| Mesalamine (Dosing Cup) | EXPERIMENTAL | One 500mg capsule contents emptied into a dosing cup and taken with water |
| MMX Mesalamine (30mg/kg) | EXPERIMENTAL | - |
| MMX Mesalamine (60 mg/kg) | EXPERIMENTAL | - |
| MMX Mesalamine (100 mg/kg) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MMX Mesalamine/Mesalazine (Low Dose) | DRUG | Once daily, tablets - the amount depends on the participants weight; 900 milligram per day (mg/day) for participants weighing 18 kg to less than or equal to (\<=) 23 kilograms (kg); 1200 mg/day for participants weighing greater than (\>) 23 kg to \<= 35 kg; 1800 mg/day for participants weighing \> 35 kg to \<= 50 kg; 2400 mg/day for participants weighing \> 50 kg to \<= 90 kg. |
| MMX Mesalamine/Mesalazine (High Dose) | DRUG | Once daily, tablets - the amount depends on the participants weight;1800 mg/day for participants weighing 18 kg to \<= 23 kg; 2400 mg/day for participants weighing \> 23 kg to \<= 35 kg; 3600 mg/day for participants weighing \> 35 kg to \<= 50 kg; 4800 mg/day for participants weighing \> 50 kg to \<= 90 kg. |
| SPD476, MMX™ mesalazine, 1.2g extended release tablet | DRUG | SPD476 1.2g administered Once Daily (QD) |
| SPD476, MMX™ mesalazine, 2.4g extended release tablet | DRUG | SPD476 2.4g administered Once Daily (QD) |
| SPD476, MMX™ mesalazine, 4.8g extended release tablet | DRUG | SPD476 4.8g administered Once Daily (QD) |
| Placebo | DRUG | Placebo administered Once Daily (QD) |
| SPD476 (1.2g) | DRUG | 1.2g SPD476 once daily (QD) orally |
| SPD476 (2.4 g) | DRUG | 2.4g SPD476 QD orally |
| SPD476 (4.8 g) | DRUG | 4.8g SPD476 QD orally |
| SPD476 | DRUG | 2.4 g/day Once Daily (QD) |
| Asacol | DRUG | 1.6g/day administered 800 mg Twice Daily (BID) |
| SPD476 (mesalazine) | DRUG | - |
| Mesalamine | DRUG | - |
| MMX Mesalamine | DRUG | 30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days. |
Inclusion Criteria: 1. Ability to voluntarily provide written, signed, and dated (personally or via a legally authorized representative \[LAR\]) informed consent or assent as applicable to participate in the study. 2. Subject's parent/LAR demonstrates an understanding, ability, and willingness to f...
Mesalamine is a small molecule drug candidate that Takeda Pharmaceutical Company Limited is developing. It is in Phase 1 clinical development, and the specific therapeutic indication has not been disclosed. Mesalamine is also known by the development code SHP429.
Mesalamine targets ALOX5, PTGS2, PTGS1, and PPARG. It is classified as an inhibitor of these targets. By acting on these molecular targets, mesalamine is designed to modulate the biological pathways associated with them.
Takeda Pharmaceutical Company Limited is developing mesalamine. Takeda trades under the ticker TAK. The company is responsible for the clinical development of this small molecule candidate.
Mesalamine is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 program includes one completed trial.
Mesalamine has been studied in one completed Phase 1 trial, NCT02125292, titled Taste Assessment Study of SHP429 in Healthy Adult Subjects. The trial enrolled 18 healthy adult volunteers in the United States and was randomized and controlled.
Yes, mesalamine is also known by the development code SHP429. The two names refer to the same investigational drug candidate being developed by Takeda Pharmaceutical Company Limited.